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Previous women’s health practitioners and researchers have postulated that some women are 
particularly sensitive to hormonal changes occurring during reproductive events. We hypothesize 
that some women are particularly sensitive to hormonal changes occurring across their 
reproductive lifespan. To evaluate this hypothesis, we reviewed findings from the existing 
literature and findings from our own lab. Taken together, the evidence we present shows a 
recurring pattern of hormonal sensitivity at predictable but different times across the lifespan of 
some women (i.e., menarche, the premenstrual phase, hormonal contraceptive use, pregnancy, 
the postpartum period, and menopause). These findings provide support for the hypothesis that 
there is a subgroup of women who are more susceptible to physical, psychological, and sexual 
symptoms related to hormonal shifts or abrupt hormonal fluctuations that occur throughout the 
reproductive lifespan. We propose that this pattern reflects a Hormonal Sensitivity Syndrome. 
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A number of women’s health practitioners and researchers have postulated that certain 
women may be more sensitive than others to hormonal changes associated with reproductive 
events [1-7]. While there is ample evidence that some women experience adverse symptoms 
related to various reproductive events [for example see 8], only a minority of these studies [for 
example see 9-10] have investigated how the experience of adverse symptoms during one 
reproductive phase may relate to other reproductive phases. Furthermore, these studies have 
generally focussed on emotional symptoms, and have not concurrently looked at physical and 
sexual symptoms. To our knowledge, no study as of yet has looked at the experience of adverse 
hormonal shift symptoms across the entire female reproductive life-span. Thus, the purpose of 
the present paper was to explore hormonal sensitivity across the entire female reproductive life-
span by examining previous research findings and reanalyzing a large dataset from our own 
laboratory. 
Hypothesis: 
We hypothesized that there exists a specific and identifiable subgroup of women who 
may experience a pattern of physical, sexual, and emotional symptoms associated with two or 
more hormonal reproductive events across their life-spans. We also argue that, once identified, 
this subgroup of women might also differ on other relevant hormonal and clinical variables, 
which may help clinicians prospectively identify and predict which women will experience this 
lifespan pattern. We propose that such a pattern may be considered a Hormonal Sensitivity 
Syndrome (HSS), reflecting a sensitivity to endogenous or exogenous gonadal hormone shifts.  
Evidence of hormonal sensitivity provided by existing research 
  
Physical and emotional symptoms are reported to varying degrees by women in response 
to hormonal shifts experienced during various reproductive phases. For instance, puberty, which 
for females usually begins between the age of 9 and 10 years old, has been associated not only 
with physical changes, such as breast development and the appearance of pubic hair [11], but 
also with the emergence of psychological difficulties for some girls. For example, the ratio of 
girls to boys who suffer from depression is approximately equal prior to puberty but shifts to a 
2:1 (or even higher) female to male ratio after puberty [12-14]. Although there are many 
competing hypotheses as to why this shift may occur, one explanation focuses on the changes in 
hormones during the pubertal period [15]. Specifically, some researchers have suggested that 
negative mood during puberty in girls could be a result of higher levels of testosterone and 
cortisol, lower levels of dehydroepiandrosterone sulphate (DHEA-S), and/or rapidly increasing 
estradiol levels [16]. In contrast, others theorize that it is not the hormone levels per se, but rather 
that some girls and women are more sensitive to hormonal shifts or relatively abrupt changes, 
and it is this sensitivity that is responsible for the resulting symptoms [8]. 
After puberty, hormonal changes across the menstrual cycle can also be associated with a 
variety of physical and psychological symptoms, albeit to varying degrees and intensities. 
Epidemiological studies have found that approximately 80 to 90 percent of menstruating women 
report at least one premenstrual symptom. Approximately 10 to 20 percent of menstruating 
women have moderate premenstrual symptoms, and 3 to 8 percent have severe symptoms that 
result in significant impairment [17]. Although definitions of premenstrual syndrome (PMS) or 
premenstrual symptoms vary, they include physical, behavioral, and emotional symptoms that 
occur during the late luteal phase of the menstrual cycle [18]. Currently, the etiology of PMS is 
unknown. However, it has been suggested that fluctuations in estrogens and progestins are 
  
partially responsible [18] and that some women are particularly sensitive to these hormonal 
fluctuations [8]. 
Pregnancy and the postpartum period are other phases in women’s lives that are 
associated with varying physical and emotional symptoms, which are often attributed to the 
significant hormonal shifts that occur during these reproductive events. Specifically, during 
pregnancy, gastrointestinal complaints are particularly common [19]. Although the cause of 
gastrointestinal complaints during pregnancy is not fully understood, increases in chorionic 
gonadotropin, progesterone, and/or estradiol levels have been suggested. Other physical 
symptoms include fatigue, breast tenderness, frequent urination, and changes in appetite [20]. 
Some women experience depressive symptoms during pregnancy or the postpartum period, 
which in approximately 7 to 12 percent and 13 to 19 percent of cases (respectively) meet the 
criteria for a clinical diagnosis of major depressive disorder [21-22]. Individual differences in 
women’s experience of the various prenatal and postnatal symptoms suggest differential 
sensitivity to hormonal change or hormone levels during these reproductive events. 
Hormonal contraceptive use is very common in reproductive-aged women, particularly in 
industrialized countries, and the use of these exogenous hormones causes hormonal shifts that, 
for some women, are related to both physical and psychological side effects [23]. Hormonal 
shifts are due to increases in exogenous hormones and resulting changes in endogenous 
hormones. Physical side effects may include bleeding irregularities, nausea, weight gain, breast 
tenderness, and headaches [24]. Further, while research suggests that many women who are 
taking oral contraceptives (OC) experience less variability in affect across the menstrual cycle or 
in response to mood primes, and less negative affect during the menstrual phase of their cycle, 
some women experience emotional side effects distressing enough to result in discontinuation or 
  
a change in type of OC [4,24-25]. Some women also experience side effects related to sexual 
functioning (i.e., decreased frequency of sexual thoughts, decreased psychosexual arousability) 
or report negative changes in mood [for example see 26]. Women are reported to be at an 
increased risk for OC negative mood side effects if they have a history of depression or other 
symptoms of psychological distress, premenstrual mood symptoms prior to OC use, 
dysmenorrhea, a history of pregnancy-related mood symptoms, or being in the postpartum period 
[see review in 4]. Hence, OC side effects have been linked to symptoms during other 
reproductive events characterized by hormonal shifts, lending support to the idea of a HSS. 
Menopause is the last major hormonal milestone experienced by women that is also 
associated with both physical and psychological effects. Vasomotor symptoms, including hot 
flashes, hot flushes, and night sweats, as well as vulvovaginal symptoms, appear to be 
specifically related to hormonal changes in menopause [27-29]. Further, research suggests that 
the perimenopausal transition is related to an increased number of depressive symptoms for 
many women [30], which may also be a consequence of the hormonal shifts experienced during 
this transition. 
Considering that both physical and psychological consequences are associated with 
various hormonal shifts for many women, it would be beneficial to know if some women are 
more susceptible than others to experiencing physical and/or psychological symptoms during any 
significant hormonal shifts across their life-span. As hormonal shifts occur over the course of an 
approximately 50-year lifespan, it is very challenging for researchers to prospectively investigate 
the symptom course over such an extensive period of time. However, the few studies that have 
retrospectively or concurrently investigated the association of the experience of symptoms 
  
between some of these reproductive phases have found that some women are more susceptible 
than others to the experience of symptoms related to hormonal shifts [for example see 30]. 
A few studies have found associations between the experience of negative symptoms 
during two or more reproductive events during the reproductive years. For instance, premenstrual 
irritability has been reported to be associated with depression during pregnancy and the 
postpartum period [10]. As well, Premenstrual Dysphoric Disorder (PMDD), mood symptoms 
experienced during the first 2 to 4 days postpartum, a past history of depression, and mood 
symptoms during past oral contraceptive use were found to be significant risk factors for 
postpartum depression [9]. A history of postpartum depression, past depressive episodes, a 
family history of affective disorders, past PMDD, and mood symptoms during the third trimester 
of pregnancy were all significantly associated with postpartum depressive symptoms in the first 
1 to 3 days postpartum [31]. Similarly, in a more recent large population-based study, Sylvén and 
colleagues [32] found a positive association between self-reported postpartum depression and a 
history of PMS or PMDD. In contrast, one study that examined whether postnatal depressive 
symptoms predicted subsequent premenstrual distress did not report a significant association 
[33]. 
There have also been a few studies that have included the perimenopausal transition 
when specifically examining the relationship between mood changes across reproductive events. 
In this research women who reported high psychological distress during menopause also reported 
more psychological distress associated with past reproductive events. Women who had high 
psychological distress during the perimenopausal period reported a history of psychological 
distress associated with: the premenstrual period, the use of oral contraceptives, and the 
postpartum period [34]. Flores-Ramos and colleagues found that menopausal women who were 
  
suffering from depression were significantly more likely to have suffered from PMDD and 
postpartum depression in the past, compared to those who were not depressed during the 
menopausal transition [35]. As well, a significant positive correlation between premenstrual and 
perimenopausal mood ratings, as well as another significant correlation between postpartum and 
perimenopausal mood ratings has been reported by Gregory and colleagues [36]. Furthermore, 
depressed mood during the menopausal transition has been reported to be significantly correlated 
with depressed mood during the premenstrual period [37]. However, Becker and colleagues did 
not find a significant association between depressed mood during perimenopause and emotional 
difficulties in the postpartum period [37]. In related research, Richards and colleagues found that 
women with perimenopausal depression were significantly more likely to meet the criteria for 
PMDD than were perimenopausal women who were not suffering from depression [38]. As well, 
Payne and colleagues found that premenstrual mood symptoms were associated with postpartum 
and postmenopausal mood symptoms [39]. However, a similar study conducted by Steinberg and 
colleagues found that neither premenstrual dysphoria nor postpartum depression were significant 
predictors of perimenopausal depression [40]. Taken together the majority of relevant studies 
suggest that there is a link between depressed mood across reproductive events, up to and 
including the menopausal transition. 
Unfortunately, there is limited data available that examine the link between symptoms 
occurring across reproductive events, and almost none on non-emotional symptoms. 
Furthermore, to our knowledge there has not been one study that has looked at women’s 
experiences and symptoms (i.e., emotional, physical, and sexual) during all of the relevant 
hormonal/reproductive events (i.e., puberty, premenstrual phase, hormonal contraceptive use, 
pregnancy, postpartum period, and the perimenopausal transition). To address this gap, we have 
  
included an examination of data from our lab that has allowed us to evaluate the relationship 
between physical, psychological/emotional, and sexual symptoms related to hormonal shifts 
occurring at distinct reproductive phases across the female life-span. The objective was to begin 
to evaluate the proposed hypothesis by providing longitudinal evidence of HSS (i.e., the re-
emergence of hormonal sensitivity symptoms at reproductive events over the course of the entire 
female reproductive lifespan). In addition to reproductive events characterized by hormonal shift, 
other factors believed to reflect or be influenced by hormonal variation [e.g., second to fourth 
digit ratio (2D:4D), neuroticism symptoms (emotional instability and negative affectivity)] were 
also considered in the analyses of this data to determine how they might relate to a HSS.  
Evidence of hormonal sensitivity provided by our own lab 
We re-examined data from a study of 289 perimenopausal or postmenopausal women. 
The women ranged in age from 39 to 65 years (mean [SD], 52 [4.72]). Additional demographic 
information may be found in Stone and colleagues [41] or on the corresponding author’s website. 
Detailed descriptions of many of the measures that were used in the original study are also 
available in Stone and colleagues [41]. Briefly, the measures used included: (a) a modified 
version of the Menstrual Distress Questionnaire (MDQ), which assess the severity of past 
premenstrual symptoms across seven domains (pain, concentration, behavioral change, 
autonomic reactions, water retention, negative affect, and arousal) [42]; (b) a modified version of 
the Oral Contraceptive Side Effects Scale (OC-SES), which measures the severity of adverse 
physical, emotional, and sexual effects of oral contraceptives [41, 43]; (c) the Pregnancy 
Experiences Questionnaire (PEQ), which measure physical and emotional symptoms 
experienced during pregnancy [41]; (d) the Postpartum Physical Symptoms Questionnaire 
(PPSQ), created to assess for physical symptoms experienced during the postpartum period [41]; 
  
(e) the Edinburgh Postnatal Depression Scale (EPDS) a commonly used and empirically 
validated scale that assesses postpartum depression [44-45]; (f) the Menopause-Specific Quality 
of Life Questionnaire (MENQOL), which measures symptoms experienced during menopause 
tapping four symptom domains: physical, vasomotor, psychosocial, and sexual [46-47]; and (g) 
the Neuroticism Subscale from the NEO-Five Factor Inventory - (NEO-FFI), which was 
included to explore the relationship between symptoms related to reproductive events and 
general psychological wellbeing, particularly given existing evidence of links between hormones 
and neuroticism [48-50]. We also included a measure of Second to Fourth Digit Ratio (2D:4D), 
which serves as a proxy indicator of fetal estrogen to testosterone exposure [51-53]. Lower 
2D:4D is associated with higher levels of fetal testosterone compared to fetal estrogen exposure, 
independent of sex [54]. Scale means, standard deviations, and internal consistencies obtained 




Re-examination of the data 
 Table 1 shows the inter-correlations among all variables used in the analyses. As can be 
seen in the table there are many positive associations between the experience of various 
hormonal symptoms both within and across reproductive events. While many small and medium 
effect size relationships were found, there were a few large effect size relationships across 
reproductive events. In particular, women who reported premenstrual distress were significantly 
more likely to endorse the experience of all adverse perimenopausal symptoms as measured by 
the MENQOL [e.g., r(273) = .52, p < .001 for MDQ pain and MENQOL physical; r(276) = .63, 
p < .001 for MDQ negative affect and MENQOL psychological]. As another example, physical 
  
pregnancy symptoms were also found to be related to postpartum physical symptoms [e.g., 
r(218) = .58, p < .001 for PEQ physical symptoms and PPSQ score].  
INSERT TABLE 1 ABOUT HERE 
As correlational analyses showed many positive relationships between symptoms across 
reproductive events, we next assessed if the various hormonal symptoms experienced across 
reproductive phases could be captured using exploratory factor analysis (EFA). Examination of 
the eigenvalues on the scree plot suggested the retention of four to seven factors, with no clear 
elbow or break. Thus, four-factor, five-factor, six-factor, and seven-factor solutions were 
explored.  
While all solutions provided very similar factor clusters, a six-factor solution accounting 
for 44.34% of the variance provided what appeared to be the most interpretable solution with a 
minimum number of cross-loading variables. The description of the factors in the six-factor 
solution were best represented by the following labels 1) PMS symptoms, 2) Sex drive, 3) 
Pregnancy and postpartum symptoms, 4) Menopause symptoms, 5) 2D:4D, and 6) OC side 
effects. There were moderate correlations found between factors 1 and 3 (r = .57), 1 and 4 (r = 
.52), and 3 and 4 (r = .40), which are all factors related to natural hormonal experiences (i.e., 
endogenous hormones) that involve changes in estradiol and progesterone. Thus, the experience 
of having high PMS symptoms is associated with high pregnancy and postpartum symptoms as 
well as high menopause symptoms. Similarly, high pregnancy and postpartum symptoms are 
positively related to menopause symptoms. A supplementary table presenting the six-factor 
solution is presented on the corresponding author’s website.
1
 
While the scree plot is a common and empirically supported method for determining 
number of factors used, an alternative method, Horn’s Parallel Analysis has been argued to be a 
  
superior technique for determining number of factors [55-56]. Thus, the factor analysis was 
repeated extracting three factors, accounting for 32.76% of the variance. Based on the results 
presented in Table 2 it appears that the factors represent: (1) Hormonal Symptoms, (2) Sex 
Drive, and (3) 2D:4D.  
INSERT TABLE 2 ABOUT HERE 
Note that the variable Sex Drive (prior to menopause) loaded negatively onto factor 3 
(2D:4D), while MENQOL Sexual Symptoms loaded positively. There were trivial to small effect 
size correlations between the three factors. The Hormonal Symptoms factor is negatively 
correlated with the Sex Drive factor (r = -.23) and did not correlate with the 2D:4D factor (r = 
.03), while the Sex Drive factor is negatively correlated with the 2D:4D factor (r = - .13). 
The results of a cluster analysis of women’s hormonal symptom scores are presented in 
Figure 1. As can be seen in the figure, the two-group cluster analysis separated the women based 
on hormonal symptom susceptibility across reproductive phases. Those reporting minimal or no 
history of hormonal symptoms are represented in the group we labeled “No Hormonal 
Sensitivity Syndrome” (No HSS) and those with high endorsement of hormonal symptoms 
across the lifespan are represented in the group we labeled “Hormonal Sensitivity Syndrome” 
(HSS). Discriminant analysis revealed that means between group clusters differed significantly 
(p < .001) for all variables assessed apart from the OC-SES Sexual variable [Wilks’ Lambda = 
.32; χ² (18, N = 177) = 194.73, p < .001]. 
INSERT FIGURE 1 ABOUT HERE 
To assess how individuals characterized by each cluster may differ on a number of other 
variables related to hormonal variation we tested several variables, which we have detailed in a 
supplementary table presented on the corresponding author’s website.
1
 The t-tests revealed that 
  
compared to cluster 2 (HSS) women, women in cluster 1 (No HSS) indicated greater sexual 
desire (p < .05), orgasm frequency (p < .01), and higher sex drive (p < .05) prior to menopause; 
as well as greater current sex drive (p < .01). Also, compared to cluster 1 (no HSS), women in 
cluster 2 (HSS) had higher neuroticism scores (p < .001). No differences were found for: body 
mass index, 2D:4D, age at menopause, age at menstruation, average cycle length, masturbation 
prior to menopause, or number of sexual partners.  
Chi-square analyses showed that compared to women in cluster 1 (no HSS), women in 
cluster 2 (HSS) were also more likely to report use of hormone replacement therapy during the 
menopausal transition (p < .05), a history of some form of reproductive surgery prior to the 
menopausal transition (p < .05), history of antidepressant use (p < .05), and experiencing at least 
one pregnancy (p < .05). No differences were found with respect to the endorsement of polycystic 
ovarian syndrome symptoms or ever receiving a formal diagnosis of either endometriosis or 
postpartum depression.  
Integration of the evidence supporting the existence of a Hormonal Sensitivity Syndrome  
The primary aim of this article was to explore whether there may be a subgroup of 
women who could be described as having what we have defined as a HSS. That is, are there 
women who appear more prone to experiencing adverse symptoms related to hormonal shifts 
occurring over their life span? It appears from our review of the existing research and the 
reanalysis of our own data that there may indeed be a subset of women who are more susceptible 
to the experience of physical, psychological, and sexual symptoms related to hormonal shifts or 
abrupt hormonal changes across the lifespan. 
To evaluate our hypothesis, we reviewed the findings from previous studies related to 
hormonal shifts experienced over the life-span. The previous literature, which evaluated 
  
symptoms or negative experiences emerging in association with two or more reproductive events 
over the reproductive life-span, suggests that a subgroup of women with hormonal sensitivity 
exists. The emergence of symptoms at one event appears associated with the emergence of 
symptoms at subsequent hormonal events or was related to the experience of symptoms at 
previous events. The reproductive events investigated in this literature included menarche, the 
menstrual cycle, use of hormonal contraceptives, pregnancy, the postpartum period, and 
menopause. We also re-examined some of our own data using two different types of analyses, 
factor analyses and a cluster analysis. The primary findings from these analyses was that three 
readily interpretable factors emerged: Hormonal Symptoms, Sex Drive, and 2D:4D. Factor 1 
appears to include symptoms related to all the major hormonal shifts across the female life span 
that are primarily characterized by changes in estrogens and progestins. The strong 
intercorrelations between all of these symptoms resulted in all of the symptoms loading onto one 
factor, supporting the HSS hypothesis.  
Moreover, cluster analysis provided further support for the existence of HSS and 
suggested a method to classify women with and without the syndrome (or those low and high on 
HSS symptoms), and allowed us to further explore the distinguishing features of the groups. 
When only looking at symptoms related to reproductive events involving hormonal shifts, two 
distinct groups of women were identified using a cluster analysis. The first cluster comprised 
women who were low on the endorsement of symptoms related to life-span hormonal shifts. The 
second cluster comprised women who more readily endorsed symptoms related to hormonal 
shifts across the reproductive life-span. Women in cluster two with HSS were more likely to 
report: (a) using hormone replacement therapy, (b) a history of reproductive surgery, and (c) a 
history of antidepressant use, which speaks to the severity and legitimacy of the women’s 
  
experiences. Also interesting is that the women in the HSS cluster were more likely to report a 
history of pregnancy. Women in cluster one without HSS endorsed higher sex drive, sexual 
desire, and frequency of orgasm; and a notably lower level of neuroticism symptoms compared 
to women in cluster two.   
It is striking that women who were not classified as having HSS were the ones who 
reported higher sex drive, sexual desire, and orgasm occurrence.  As women's sexual desire and 
motivation is modulated by ovarian hormones [for example see 57], which are positively 
associated with estradiol and negatively associated with progesterone, the non-HSS women 
identified here are clearly hormonally sensitive in terms of their sexual response [58]. It may be 
that the women identified here as having a HSS are those women: (a) who are most likely to 
experience adverse emotional and physical symptoms with decreasing or decreases in 
endogenous estradiol and progesterone levels (as in the premenstrual phase, postpartum period, 
menopausal period, or with oral contraceptive use), or (b) who do not experience high sexual 
desire and behaviour in response to normal/high levels of estradiol. Thus, while it is possible that 
the cluster analysis differentiated between a group with HSS and one without, it is also possible 
that the cluster analysis differentiated between two different types of hormonally sensitive 
women, one group with a negative HSS and one with a positive HSS. In this second possibility, 
women with a negative HSS would experience adverse physical and emotional symptoms with 
extreme hormone levels (very low and possibly very high levels such as in pregnancy) whereas 
the women with positive HSS may remain sexually responsive to estradiol throughout a larger 
range of hormone levels. Alternatively, positive HSS women may maintain the ideal ratio of 
hormones when hormone levels fall or they may have some other feedback mechanism that helps 
their sexual response system adapt to the drop in hormone levels. The positive HSS group may 
  
be a group of women who are simply more hormonally sensitive or responsive to the positive 
effects of estradiol on sexual feelings and behaviour. While the present findings may well reflect 
two different types of HSS, a positive sexual HSS does not appear to be the cause of significant 
distress or impairment in women. Thus, at this time, a single HSS appears to be the most useful 
interpretation of the evidence.  
It is difficult to implicate specific hormones that women endorsing HSS may be sensitive 
to. It is likely a combination of hormonal shifts that are responsible for the variety of symptoms 
experienced by some women during these reproductive phases. However, as all of the hormonal 
shifts involve changes in endogenous or exogenous estrogens, progestins, or androgens, it is 
possible that a sensitivity to shifts in these hormones in particular plays a central role in HSS. 
One possibility is that HSS, and women’s susceptibility to symptoms as a result of these shifts, 
may be the result of one or more genetic polymorphisms or some other vulnerability [59]. 
Further research is needed to identify genetic and other variables that differ between these two 
clusters of women (i.e., those with and without HSS). The use of cluster analytical techniques to 
group women into those who are low and high on HSS, as done here, may be one useful strategy 
for identifying these two groups of women and determining other identifying characteristics or 
predictors of HSS. 
There was agreement between the three-factor structure, six-factor structure, and the 
cluster analysis in suggesting that neuroticism was associated with HSS. While the three-factor 
solution provides a more readily interpretable factor structure, both sets of factor analyses are 
discussed here as they each provide a unique and valuable perspective on hormonal sensitivity. 
With the exception of menopausal psychological symptoms, the six-factor analysis separates the 
reproductive shifts by specific events, yet correlational analyses of the factors revealed moderate 
  
correlations between events related to shifts in endogenous hormones. When examining the 
three-factor structure, all symptoms related to all reproductive shifts load onto the same factor, 
apart from sexual side effects related to OC use. The latter symptoms negatively loaded onto the 
sex drive factor (the direction theoretically expected), though it did not reach our threshold 
criteria of ≥ .30. Taken together this appears to suggest that there may be something unique about 
women’s sex drive and sexual experiences related to exogenous hormone use. Furthermore, the 
three-factor structure highlights that there is a relationship between various forms of 
symptoms/side effects related to individual reproductive events. The six-factor structure 
provided evidence of an even stronger relationship between reproductive events with naturally 
occurring hormonal shifts. Finally, a relationship further emerges between symptoms related to 
all reproductive events, signifying a HSS. That is, each analysis presented above provided 
evidence of HSS while providing some additional information about predictors of HSS. 
In addition, we also examined the relationships between the isolated hormonal events. 
The correlation matrices suggest consistent associations between symptoms experienced during a 
number of reproductive events throughout the female life-span from gestation through to the 
perimenopausal transition. Specifically, low 2D:4D (i.e., higher prenatal testosterone or lower 
prenatal estradiol exposure) is associated with higher menopausal/postmenopausal sex drive for 
women during/after menopause. It may be that a positive influence of prenatal androgen 
exposure (or a negative influence of prenatal estradiol exposure) on sex drive is unmasked during 
menopause with the reduction in estradiol and progesterone. We are not aware of any previous 
report of an association between 2D:4D and sex drive or menopausal symptoms. However, 
unpublished data from our lab has not found any significant associations between 2D:4D and sex 
drive in premenopausal young women. This finding of an association between digit ratio and sex 
  
drive in women at/after menopause suggests a possible organizational role for prenatal hormones 
on sex drive (i.e., high prenatal androgen exposure and low prenatal estradiol exposure 
associated with higher sex drive) that may only become apparent, unmasked, or measurable after 
menopause once the activating effects of circulating estradiol and progesterone have been 
removed. 
Further, our correlational results suggest that women who experience premenstrual 
distress are also likely to experience OC side effects and a variety of symptoms related to 
pregnancy, the postpartum period, and menopause. This seems to indicate that premenstrual 
distress may be an early indicator of HSS. This observation is further supported by the results of 
the cluster analysis which distinguished women based on high or low endorsement of hormonal 
symptoms across all of these reproductive phases. Such women differed in that women with HSS 
had higher neuroticism scores, and were more likely to have experienced at least one pregnancy, 
to have had reproductive surgery, and to have taken antidepressants than women without HSS. 
Thus, women with HSS experience more distress than women without HSS as evidenced by 
surgical and pharmaceutical interventions that have putative hormonal relevance. 
As well, correlational analyses also showed that women who reported greater OC side 
effects reported more symptoms related to pregnancy, the postpartum period, and the 
perimenopausal transition. Emotional and physical symptoms during pregnancy were related to 
postpartum emotional and physical symptoms, and symptoms during each of these time points 
were associated with the experience of more symptoms during the perimenopausal transition. 
The notion that some women are more susceptible to hormonal shifts stems from research 
that has found that women experiencing symptoms related to isolated reproductive phases do not 
have hormone levels that differ significantly from women who do not report symptoms related to 
  
the same time periods. Investigation into the potential differences in hormone levels between 
women with and without particular psychological symptoms, especially depression, has been a 
primary focus of research. The results from our retrospective data suggest associations between 
the experience of physical and psychological symptoms both within and across different 
reproductive phases (e.g., women who experience high levels of negative affect during the 
premenstrual/menstrual phase also experience high levels of physical symptoms at menopause, r 
= .49). This finding supports the HSS hypothesis and suggests the importance of further research 
into the potential endocrinological processes that are responsible for psychological and physical 
hormonal symptoms, both in isolation and unison. 
In interpreting the new findings we present, there are some considerations that should be 
taken into account. First, as our results are based on retrospective data, accuracy of participant 
recall is a potential limitation. However, questions posed to participants were in reference to 
events that are not only salient (e.g., pregnancy) but often also occur repeatedly over many years 
(e.g., the premenstrual phase), which, theoretically, should increase the reliability of responses. 
Second, while the reliability of this work would be augmented using a prospective design, we are 
considering events that occur over a period of roughly 50 years, which is a significant strength of 
our study. Logistically speaking, a prospective design would not only be a tremendously 
challenging endeavour for a research team, it would also likely be compromised by participant 
attrition. Third, the methodology we employed to obtain the data does not permit us to determine 
directionality of the associations we report, nor do the data confirm any causal relationships. 
Finally, these participants were generally well educated, which may limit the generalizability of 
our data specifically. However, we had a considerable sample size and our participants displayed 
a wide range of symptoms, which enhances the utility of our findings.  
  
Combined, the evidence from past research and the data presented from our lab suggest 
the need for additional research that might further evaluate the HSS hypothesis.  Why, for 
instance, are some women more susceptible and others less so?  What exactly are the 
mechanisms? Future research could evaluate how HSS relates to other physical and 
psychological concerns that show sex differences. It would also be useful to determine whether 
women with HSS are at greater risk for a diagnosis of disorders such as major depressive 
disorder and eating disorders [60-62], particularly given evidence of a role for hormones in each 
of these disorders [63-64]. As well, it may be valuable to investigate HSS as it relates to physical 
illnesses that are more commonly diagnosed in women, such as breast cancer and lupus [65-66].  
Subsequent researchers might re-examine some of the conditions we evaluated here (e.g., formal 
diagnosis of postpartum depression and endometriosis) as these conditions may have returned 
null findings because they have historically been underdiagnosed. It may also be valuable to 
explore the possibility that women with HSS show a kindling effect or sensitization effect on 
symptoms due to repeated exposure to hormonal shifts across the lifespan. Finally, future 
research might look at the potential positive effects of hormonal shifts as a result of reproductive 
events, as the hypothesis evaluated here was primarily concerned with the experience of adverse 
experiences or symptoms. 
CONCLUSION 
While the endocrinological mechanisms of HSS are still unclear, this review of evidence 
from the existing literature in combination with our retrospective data suggest that some women 
are more likely to experience symptoms during a number of hormonal shifts across their 
reproductive life-span. Consequently, we hypothesize that a subset of women may be classified 
as having a HSS. While some experts have recognized a connection between hormonal shifts 
  
across the female reproductive life-span, to our knowledge this is the first paper to both 
systematically examine this issue and propose that this re-occurrence of adverse symptoms 
related to reproductive events may be a result of a Hormonal Sensitivity Syndrome. To date 
research has primarily evaluated symptoms related to hormonal shifts by focusing on individual 
reproductive events in isolation. In some cases, studies have looked at the association of 
symptoms across two events. The evidence we present here supports our hypothesis for the 
existence of a HSS, or the tendency for a subgroup of women to experience adverse physical, 
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Note. The two clusters depicted in this figure represent a No Hormonal Sensitivity Syndrome Group (No HSS) and a Hormonal Sen
(HSS) and reflect the symptoms that most strongly discriminate these two groups of women. MDQ = Menstrual Distress Questionnaire; OC
Contraceptives Side-effects Scale; PEQ = Pregnancy Experiences Questionnaire; PPSQ = Postpartum Physical Symptom Questionnaire; EPDS =
Postnatal Depression Scale; MENQOL = Menopause Quality of Life Questionnaire. 
  
Table 1. Pearson’s Product-Moment Correlations Indicate Associations between Hormonally-Relevant 
Symptoms Across Reproductive Phases (N =283a) 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 
1. Right 2D:4D                 
2. Left 2D:4D .62
** 
               
3. Age of Menses .13 .16               
4. MDQ Pain -.05 -.11 -.10              
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18. Age of Menopause -.06 -.08 -.05 -.12 -.03 -.07 -.10 -.06 -.07 -.11 -.10 -.08 .01 -.07 -.18
*
 -.07 




 -.12 .00 -.05 -.12 -.09 -.08 -.12 -.08 -.09 .00 -.05 -.19
**
 -.06 
















 .04 .04 .11 .05 .17
*
 



































































 .11 .07 .14
*
 .10 .11 

























25. BMI -.10 -.14 -.25
**
 .04 .03 .06 -.06 -.12 -.07 -.04 .08 .03 -.07 -.03 .01 -.06 
Note. Shading highlights assessment subscales or similar measures based on reproductive time-point; 2D:4D = 
finger length ratio of 2nd digit to 4th digit; MDQ = Menstrual Distress Questionnaire; PCOS = Polycystic Ovary 
Syndrome; OC-SES = Oral Contraceptives Side-effects Scale; PEQ = Pregnancy Experiences Questionnaire; 
PPSQ = Postpartum Physical Symptom Questionnaire; EPDS = Edinburgh Postnatal Depression Scale; 
MENQOL = Menopause Quality of Life Questionnaire; NEO-FFI = NEO Five-Factor Inventory. 
a The maximum possible sample size for all correlations excluding those with 2D:4D variable is N = 283 (range 
N = 113 to 283); For correlations with 2D:4D variable maximum possible sample size N = 100 (range N = 53 to 
100);   
b Age of menopause subtract age of menses    
* Correlation is significant at the.05 level (2-tailed); ** Correlation is significant at the.01 level (2-tailed) 
             




Table 2. Three-Factor Analysis of the 32 Reproductive Event Measures Across the Female Lifespan 
 
Factor 
1 2 3 
 Hormonal 
Symptoms 
Sex drive 2D:4D 
Right 2D:4D .114 -.044 .670 
Left 2D:4D .130 -.129 .868 
Age of menses -.047 -.029 .175 
Sexual desire a  -.135 .862 -.050 
Orgasm a -.130 .705 -.074 
Masturbate a  -.080 .588 -.044 
Sex drive a -.164 .373 -.339 
Current sex drive -.127 .785 -.133 
MDQ Pain .703 -.113 -.206 
MDQ Water Retention .558 -.036 -.072 
MDQ Automatic  .595 -.184 -.149 
MDQ Negative Affect .836 -.194 -.044 
MDQ Concentration .790 -.228 -.162 
MDQ Behavior .763 -.216 -.099 
MDQ Arousal .370 -.067 .020 
Endometriosisb -.104 .062 -.063 
PCOSb .045 -.114 -.028 
OC-SES Physical .327 .050 .026 
OC-SES Emotional .360 .063 .057 
OC-SES Sexual .157 -.259 .007 
Ever pregnant b .095 -.056 -.153 
PEQ Physical .499 -.156 .068 






PPSQ .443 -.124 .125 
EPDS .581 -.221 .152 
Postpartum depression b -.146 .056 .104 
Reproductive life span c -.135 -.044 -.112 
MENQOL Vascular .344 -.075 .023 
MENQOL Psychological .721 -.147 .120 
MENQOL Physical .696 -.093 .041 
MENQOL Sexual .420 -.248 .278 
NEO-FFI Neuroticism .630 -.218 .190 
Eigenvalues (% variance) 6.423 2.434 1.621 
Note.  Shading represents variables considered for factor label; 2D:4D = finger length ratio of 2nd digit to 
4th digit; MDQ = Menstrual Distress Questionnaire; PCOS = Polycystic Ovary Syndrome; OC-SES = Oral 
Contraceptives Side-effects Scale; PEQ = Pregnancy Experiences Questionnaire; PPSQ = Postpartum 
Physical Symptom Questionnaire; EPDS = Edinburgh Postnatal Depression Scale; MENQOL = 
Menopause Quality of Life Questionnaire; NEO-FFI = NEO Five-Factor Inventory. 
a Prior to Menopause 
b Coded 1 (yes) 2 (no) 
c Age of menopause subtract age of menses. 
 
